Anti-Integrin therapy for retinovascular diseases.

Anti-Integrin therapy for retinovascular diseases.
Expert Opin Investig Drugs. 2020 Jul 12;:
Authors: Bhatwadekar AD, Kansara V, Luo Q, Ciulla T
Abstract
INTRODUCTION: Integrins are a family of multi-functional cell-adhesion molecules heterodimeric receptors that connect extracellular matrix (ECM) to actin in the cell cortex, thus regulating cellular adhesion, migration, proliferation, invasion, survival, and apoptosis. Consequently, integrins play a role in inflammation, angiogenesis and fibrosis.
AREAS COVERED: This review examines each anti-integrin agent in terms of its chemical nature, route of administration, and anti-integrin action. It also provides a summary of preclinical and clinical studies. Clinical candidates include risuteganib, THR-687, SF-0166, which have shown promise in treating diabetic macular edema (DME) and non-neovascular AMD in early clinical studies. Preclinical candidates include SB-267268, JNJ-26076713, Cilengitide and Lebecetin, which exhibit a decrease in retinal permeability, angiogenesis and/or choroidal neovascularization (CNV).
EXPERT OPINION: Anti-integrin therapies show potential in treating retinal diseases. Anti-integrin agents tackle the multi-factorial nature of DR and AMD and show promise as injectable and topical agents in preclinical and early clinical studies. Integrin inhibition has potential to serve as primary therapy, adjunctive therapy to anti-vascular endothelial growt...

Source: Expert Opinion on Investigational Drugs - July 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research